First AD

Second AD

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following question:

What are your final perspectives and insights on unmet needs and therapeutic advances in SCLC?

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer

Peer Exchange

Winship Cancer Institute of Emory University

Cancer Centers

Partner

Yale Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine

Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

Examining 3-Year Update Data from the CASPIAN Trial

Predictors of Immunotherapy Response in Limited and Extensive SCLC

Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

Examining the use of PD-L1 and tTMB in the CASPIAN Trial

Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC 

Examining Key Data from DAREON-8 